Mikrobiyoloji ve klinik mikrobiyoloji anabilim dalı derin mikoz laboratuarında 01 Nisan 1999-27 Mart 2001 arasında ayrılan maya ve küflerin tür dağılımları ve duyarlılık paterni

Bu çalışmanın amacı, Cerrahpaşa Tıp Fakültesi Kliniklerinden Mikrobiyo- loji ve Klinik Mikrobiyoloji Anabilim amfoterisin B, flukonazol, itrakonazol, ketokonazol, mikonazol, flusitozin ve terbinafin karşısındaki duyarlılıkları NCCLS referans M27-A ve M38-P yön- temleri ile belirlenmiştir. Toplam 146 maya ve 12 küf ayrılmış- tır. C. albicans’lar %66.4 (97/146) ve C. albicans dışı Candida’lar %33.6 (49/146) oranındadır. Ayrılan çeşitli maya türle- rinin karşılaşma sıklığı C. catenulata 1 (% 0.7), C. glabrata 6 (%4.1), C. kefyr 4 (% 2.7), C. krusei 6 (%4.1), C. lipolytica 3 (% 2.0), C. lusitaniae 1 (%0.7), C. Para- psilosis 8 (% 5.5), C. rugosa 2 (% 1.4), C. tropicalis 12 (% 8.2), M. furfur 1 (% 0.7), T. beigelii 3 (% 2.0), Cryptococcus neofor- mans 2 (%1.4)’dir. İnfeksiyon etkeni o- larak ayrılan küf mantarlarının sıklığı Aspergillus flavus 4 (%33.3), A. Fumi- gatus 2 (%16.6), A. niger 3 (%25), A. versicolor 1 (%8.3), Cladosporium clado- sporioides 1 (%8.3), Scopulariopsis can- dida 1 (%8.3) ve Cladosporium sp 1 (% 8.3)’dir. NCCLS kriterlerine göre değerlendi- rildiğinde çalışmamızda FKZ için direnç (MIC ³64 mg/ml) C. albicans kökenlerin- de 21 (%21.6), albicans dışı Candida türlerinde 19 (%38.8), İTZ’e direnç (MIC ³1 mg/ml) C. albicans kökenlerin- de 31 (%32), albicans dışı Candida’larda 15 (%30.6), 5-FC’e karşı direnç (MIC ³32 mg/ml) C. albicans kökenlerinde 5 (% 5.1), albicans dışı Candida’larda 7 (% 14.3)’dir.

The species distribution and antifungal susceptibility pattern of yeasts and molds isolated in the department of microbiology and clinical microbiology deep mycoses laboratory between 01 April 1999-27 March 2001

The purpose of this study was to characterize the species distribution and antifungal susceptibility patterns of yeast and mold strains isolated at deep mycoses laboratory, Department of Microbiology and Clinical Microbiology. The species distribution and antifungal susceptibility patterns of the clinically significant yeast and mold isolates recovered from deep mycoses suspected patients. specimens over a two year period were determined against amphotericin B, fluconazole, itraconazole, ketoconazole, miconazole, flucytosine and terbinaphyne using the M27-A and M38-P reference methods. Results.- A total of 146 yeast and 12 mould strains were isolated. C. albicans strains was %66.4 (97/146), and non-albicans Candida species were %33.6 (49/146). The frequency of various yeast species identified was Candida catenulata 1 (0.7%), C. glabrata 6 (4.1%), C.kefyr 4 (2.7%), C. krusei 6 (4.1%), C. lipolytica 3 (2.0%), C. lusitaniae 1 (0.7%), C.parapsilosis 8 (5.5%), C. rugosa 2 (1.4%), C. tropicalis 12 (8.2%), M. furfur 1 (0.7%), T.beigelii 3 (2.0%), Cryptococcus neoformans 2 (1.4%). The frequency of mold species identified Aspergillus flavus 4 (33.3%), A. fumigatus 2 (16.6%), A. niger 3 (25%), A.versicolor 1 (8.3%), Cladosporium cladosporioides 1 (8.3%), Scopulariopsis candida 1 (8.3%) and Cladosporium sp 1 (8.3%). Resistance to fluconazole (MIC > or = 64 micrograms/ml) as per NCCLS criteria was observed in 21 C. albicans (21.6%), 19 non-albicans Candida strains (38.8%); resistance to itraconazole (MIC > or = 1 micrograms/ml) in 31 C. albicans (32.2%), 15 nonalbicans Candida strains (30.6%) and resistance to flucytosine (MIC > or = 32 micrograms/ml) in 5 C. albicans (5.1%), 7 non-albicans Candida strains 7 (14.3%). Conclusion.- The present study indicates that Candida sp. are emerging as important pathogens in immunocompromised patients and the tendency of yeasts to develop resistance to antifungal agents and the appearance of species/strain specific susceptibility of molds, in vitro tests seem to be useful for patient management.

PDF

___

1. Dupont B. Changing prevalence in systemic füngal infections. Abstracts of 5th Congress of the European Confederation of Medical Mycology (3-6 June 1999,«Dresden, Germany). Mycoses 1999; 42: 131.
2. Lorf T, Braun F, Ruchel R, Muller A, Sattler B, Ringe B. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 1999; 1-2: 47-53.
3. Anaissie E. Opportunistic mycosis in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14:43-53.
4. Bodey GP, Rolston KVI. Deep fungal infections. In: Armstrong D, Cohen J (eds). Infectious Diseases. London: Mosby, 1999; 2.7.1-2.7.20.
5. van't Wout JW. Fungal Infections a&d antifungal drugs: has the.age of ajitifungal resistance dawnedTCurrent Opinion m Infection Diseases -1806; 9: 63-66.
6. Murray PR, %tron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology. 6th ed. Washington DC: asm Press, 1995; 709-722.
7. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Washington CW Jr (Eds). Diagnostic Microbiology. Fifth edition. Philadelphia: Lippincott, 1997;
8. Buchanan KL. What makes Cryptococcus neoformans a pathogen? Emerging Infect Dis 1998; 4: 16-22.
9. Hamilton AJ, Goodley J. Virulence factors of Cryptococcus neoformans. Curr Top Med Mycol 1996; 19-42.
lO.Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 2: 310-350.
11. Denning DW. Invazive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
12. Wong-Beringera A, Hindler J, Barankovic L, Muehlbauer L, Steele-Moore L. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients. Diagn Microbiol Infect Dis 2001; 1: 25- 31.
13.Waltimo TM, Orstavik D, Meurman JH, Samaranayake LP, Haapasolo M. In vitro ■ susceptibility of Candida albicans isolates from . apical and marginal periodontitis to common antifungal agents. Oral Microbiol Immunol 2000; 4: 245-248.
14. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
15.McGinnis MR, Rinaldi MG. Antifungal drugs: mechanism of action, drug resistance, susceptibility testing, and assay of activity in biologic fluids. In: Lbrian V (ed). Antibiotics in Laboratory Medicine. Williams and Wilkins, Baltimore, 1996; 176-311.
16. Espinel-Ingroff A, Pfaller MA. Antifungal agents and susceptibility testing. In: Murray P, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology. Washington DC: ASM Press, 1995; 1405.
17. Rex J, Pfaller M, Galgiani J, Bartlett MS, Espinel-Ingroff A, Ghannoum M, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry A. Development of interpretive breakpoints for antifungal susceptibility testing: conseptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-247.
18. National Committee for Laboratory Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts. Approved Standard; Document M27-A National Committee for Laboratory Standards.Villanova, 1997;
19. National Committee for Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi; Proposed Standard. Dpcument M38-P. National Committee for Laboratory Standards. Wayne, 1998;
20. Ellis D, Pfeiffer T. Antifungal susceptibility testing for clinical microbiology laboratory. ISHAM Mycoses Newsletter 2001; 75: 3-4.
21. Kaufman L. Laboratory methods for the diagnosis and confirmation of systemic mycosis. Clin Infect Dis 1992; 14: 23.
22. Richardson MD, Kokki MH. New perspectives in the diagnosis of systemic fungal infections. Ann Med 1999; 31: 327-335.
23.Barnett JA, Payne RW, Yarrow D. Yeasts: Characteristics and Identification. 2nd ed. Cmbridge: Cambridge University Press, 1990;
24.Lodder J. The Yeasts. A Taxonomic Study. Amsterdam: North Holland Publishing Co, 1979.
25. Kwon Chung KJ, Bennett JE. Medical Mycology. Philadelphia; Lea and Fabinger, 1992;
26. Cooper BH, Silva-Hutner M. Yeasts of Medical Importance. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ (eds). Manual of Clinical Microbiology. 4th ed. Washington DC: asm Press 1985; 526-541.
27. de Hoog GS, Guarro J. Atlas of Clinical Fungi. Centralbureau voor Schimmelcultures, Delft, the Netherlands and Universitat Rovira i Virgilli, Reus, Spain 1995;
28. Warren N, Kevin CH. Candida, Cryptococcus and other yeasts of medical impotrance. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology. Washington DC: ASM Press, 1995; 723-737.
29.Nenoff P, Haustein UF. In vitro susceptibility teting of Malassezia furfur against rilopirox. Skin Pharmacol 1997; 10: 275-280.
30. Nenoff P, Oswald U, Haustein U-F. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test. Mycoses 1999; 42: 629-639.
31. Odds FC. Candida and Candidosis. London: Bailliere Tindall 1988;
32. Coleman D, Sullivan D, Harrington B, Haynes K, Henman M, Shanley D,et.al. Molecular and phenothypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Diseases 1997; 3: 96-101.
33. Wingard JR. Importance of Candida species other than C.albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-125.
34. Granier F. Invazive fungal infections. Epidemiology and new therapies. Presse Med 2000; 37: 2051-2056.
35. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Mayer K, Duerr A, Vazquez JA, Rampalo A, (HIV)-seropositive and at-risk HIV- seronegative women. J Infect Dis 2001; .2: 286- 293.
36. Chadeganipour M, Shadzi S, Dehghan P, Bijary J. The incidence of opportunistic fungi in patients suspected of tuberculosis. Mycosis 2000; 43: 269-272. "37. Wingard JR. Importance of Candida species other than C.albicans as pathogens in oncology ', ■ patients. Clin Infect Dis 1995; 20: 115-125.
38. Fowler SL, Rhoton B, Springer SC, Messer SA, Hollis RJ, Pfaller MA. Evidence for person-to- person transmission of Candida lusitaniae in a neonatal intensive-care unit. Infect Control Hosp Epidemiol 1998; 19: 343-345.
39. Arıkan S, Hasçelik G, Günalp A. Hacettepe Üniversitesi hastanelerinde klinik örneklerden izole edilen maya türleri. İnfeksiyon Derg 1998; 1: 97-102.
40. Agel HE, Durmaz B, Refik M, Dikerel Ş. Turgut Özal Tıp Merkezi'nde çeşitli klinik örneklerden izole edilen Candida'larm türlere göre dağılımı. Turgut Özal Tıp Merkezi Dergisi 1999; 4: 1-3.
41. Ener B, Akalın H, Akçağlar S, Helvacı S, Töre O. Yüzeyel ve derin mikozlarda küf mantarları. İnfeksiyon Derg 1999; 13: 99-103.
42. Kantarcıoğlu AS, Yücel A. Aspergillus türleri ve invaziv aspergilloz: mikoloji, patogenez, laboratuvar tanımı, antifungallere direnç ve duyarlılık deneyleri (Cerr Tıp Fak Dergisine sunulmuştur)
43. Araj GF, Daher NK, Tabbarah ZA. Antifungal susceptibility of Candida isolates at the American University of Beirut Medical Center. Int J Antimicrob Agents 1998; 4: 291-296.
44. Magaldi S, Mata S, Hartung C, Verde G, Deibis L, Roldan I, Marcano C. In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs. Mycopathologia 2001; 2: 63-68.
45. Arıkan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of Amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37: 3946-3951.
46. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229-234.
47.Mosquera J, Warn P, Moore C, Denning D. Azole cross resistance in Aspergillus fumigatus. 11th European Congress of Clinical Microbiology and Infection Diseases (1-4 April, 2001, Istanbul) abstracts. In: Clinical Microbiology and Infection 2001; 34.
48. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus infection. J Antimicrob Chemother 1997; 40: 401-414.
49. Denning DW, Venkateswarlu K, Oakley K, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364-1368.
50. Denning DW, Warn P. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob Agents Chemother 1999; 43: 2592-2599.
51. de Pauw BE. Clinical experiences with the new antimycotic UK 109 496 (Voriconazole) in clinical trials. Abstracts of 5th Congress of the European Confederation of Medical Mycology (3-6 June 1999, Dresden, Germany). Mycoses 1999; 42: 149-150.